-
-
-
-
-
-
-
Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales
-
-
-
-
-
-
-
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
-
-
-
-
-
-
-
Biogen earnings preview Q4: set for weaker print, Leqembi outlook in focus
-
-
-
-
-
-
-
Biogen (BIIB) Tops Q3 EPS by 93c; updates guidance
-
-
-
-
-
-
-
U.S. large biotech stocks Q2 earnings preview
-
-
-
-
-
-
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
1,232,346 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


